Personalized medicine—a modern approach for the diagnosis and management of hypertension

Carmine Savoia¹, Massimo Volpe¹,², Guido Grassi³, Claudio Borghi⁴, Enrico Agabiti Rosei⁵ and Rhian M. Touyz⁶

¹Clinical and Molecular Medicine Department, Cardiology Unit Sant’Andrea Hospital, Sapienza University of Rome, Rome, Italy; ²IRCCS Neuromed, Pozzilli (Is), Italy; ³Clinica Medica, Department of Medicine and Surgery, University Milano-Bicocca, Milan, Italy; ⁴Chair of Internal Medicine, Department of Medical and Surgical Sciences, Faculty of Medicine, University of Bologna, Bologna, Italy; ⁵Department of Clinical and Experimental Sciences, Clinica Medica, University of Brescia, Brescia, Italy; ⁶Institute of Cardiovascular and Medical Sciences, British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, U.K.

Correspondence: Carmine Savoia (carmine.savoia@uniroma1.it)

The main goal of treating hypertension is to reduce blood pressure to physiological levels and thereby prevent risk of cardiovascular disease and hypertension-associated target organ damage. Despite reductions in major risk factors and the availability of a plethora of effective antihypertensive drugs, the control of blood pressure to target values is still poor due to multiple factors including apparent drug resistance and lack of adherence. An explanation for this problem is related to the current reductionist and ‘trial-and-error’ approach in the management of hypertension, as we may oversimplify the complex nature of the disease and not pay enough attention to the heterogeneity of the pathophysiology and clinical presentation of the disorder.

Introduction

Hypertension occurs in more than one billion individuals, and its prevalence appears to affect approximately 40% of the general population, with an increase upon aging from 7% in younger individuals (18–39 years old), to 65% in individuals over 59 years old [1]. Hypertension represents the most relevant risk factor for death and disability worldwide, causing an estimated 9.4 million deaths every year [2]. Hypertension contributes 3.5 times more to the total global disease burden of cardiovascular disease than smoking and 1.6 times that of hypercholesterolemia [3]. Prospective cohort studies have reported a continuous log-linear association between blood pressure and vascular events beginning at values of 115/75 mmHg with no apparent threshold [4–9]. The burden of hypertension and its associated atherosclerotic target organ complications are increasing as the population increases in size, age, and obesity [10]; this association seems to exist across large and diverse population groups from several ethnicities, with and without established vascular disease [4,11,12]. Nevertheless, hypertension contributes to an unequaled burden of disease globally [13], for example, Western European countries exhibit a downward trend, in contrast with Eastern European countries, which show an increase in death rates from stroke [14,15].

Tissue and organ remodeling processes induced by hypertension may impair the physiology and structure of the heart, arteries, kidneys, and brain. Thus, the presentation of target organ complications in
hypertensive patients may reflect different pathophysiological abnormalities including: diastolic and systolic dysfunction, left ventricular hypertrophy, congestive heart failure (39% of cases in men and 59% in women), coronary disease, accelerated atherosclerosis, aneurysm formation, stroke, nephrosclerosis, and renal failure [16]. Approximately 50% of hypertensive patients develop related end-organ damage if blood pressure is untreated or not treated to target. Yet hypertension remains the most common modifiable risk factor for cardiovascular disease [10]. The net benefit derived from antihypertensive therapy has been demonstrated in clinical trials and is associated with reduction in stroke (35–40%), myocardial infarction (20–25%), and in heart failure incidence (50%) [17-28]. In particular, a 10 mmHg reduction in systolic blood pressure is associated with a 22% reduction in coronary heart disease and 41% reduction in stroke, with a slight difference in reduction in cardiometabolic mortality for men (46%) and women (41%) [29]. Interestingly, mortalities attributable to heart attack and stroke are declining, whereas the incidence and prevalence of heart and kidney failure are rising [14]. This is mainly due to the therapeutic targeting of structural vascular alterations that lead to increased stiffness of large and small arteries in hypertensive patients, particularly if diabetes is associated [30-32].

For over a decade, international guidelines for the management of hypertension have stratified cardiovascular risk into different categories, based on blood pressure values, the presence of other cardiovascular risk factors, and organ damage [33,34-39]. Accordingly, patients at high or very high cardiovascular risk require intensive cardiovascular risk-reducing measures and eventually intensive drug therapy. Nonetheless, whether blood pressure lowering treatment reduces the risk of cardiovascular disease in all types of patient populations remains unclear, particularly in the elderly, individuals with lower blood pressure values, or with comorbidities [40-43]. Hence, although a modern drug-based therapeutic approach has the capacity to reduce blood pressure in a high percentage of patients with hypertension, the best approach to reduce blood pressure remains controversial [36,44-47].

Moreover, despite increased awareness of hypertension-related complications, reductions in major risk factors, widespread availability of very good antihypertensive drugs, as well as the better use of antihypertensive therapies [1,4,33,48], the control of blood pressure to target values is still poor (only 30% of treated patients achieve blood pressure control ≤140/90 mmHg), thus the overall prevalence of hypertension has increased by approximately 10% [1,49,50]. For instance, in a large Italian population of treated hypertensive patients followed for 10 years, it has been shown that approximately 60% of hypertensive patients were treated and among these only 33% achieved effective blood pressure control [51]. These data are similar to other reports from different countries. This is mainly attributable to reduced compliance and adherence to antihypertensive treatment [52-54], which is associated with a lack of improvement in cardiovascular risk. Among the explanations for the poor adherence we should consider the variability in the individual response to a given treatment, as well as the individual, distinctive, and not always predictable occurrence of adverse events related to antihypertensive medications, which are usually not life-threatening although frustrating for the patient who eventually may decide to discontinue the therapy. This can generate a ‘trial-and-error’ approach in clinical practice that is characterized by the switching to another medication in case the first therapeutic choice was not satisfactory after few weeks. This approach is based on general information derived mainly from data of randomized clinical trials regarding the drug that might work for that particular patient. In clinical trials, individuals are enrolled under a reductionist approach that assumes the individuals have a common phenotype (i.e. elevated blood pressure), and are treated following algorithms derived from large population studies [36]. The trial results are described as the median blood pressure in a given treatment arm, which is characterized by a therapeutic regimen that does not necessarily distinguish among subtypes of patients. This ‘one size fits all’ approach is expensive and is not adapted to current biomedical research, which explores differences in disease presentation and response to therapies among individuals [55], rather it may oversimplify the complex nature of most diseases. Therefore, with this approach based on the conventional diagnostic paradigm, the descriptions of the disease become broad, focusing less on individual diversities in terms of heterogeneity in the pathophysiology, and the underlying mechanisms of the symptoms. Hence, the characterization and distinction among multiple diseases with shared symptoms are elusive [55-57]. On the other hand, a more personalized approach based on the specific disease pathology, symptoms, signs, and response to treatment of the individual patient would improve diagnosis and risk stratification. It would also identify new pathophysiological pathways, tailor the appropriate therapy in order to improve adherence, and take into account that blood pressure levels and target organ damage may differ among people, not only as a consequence of different exposures to environmental factors but also because of genetic variation in susceptibility to develop disease in response to the environment.

Major clinical guidelines, while advocating evidence-based suggestions, are not highly personalized to the pathophysiology of individual patients and fundamentally use a standard universal approach at the individual level [10]. Thus, taking into account that patients with hypertension may have a different genetic predisposition, as well as the
underlying mechanisms for high blood pressure may differ among individual patients, a more personalized and different approach to the treatment of hypertension warrants consideration in order to improve the detection, evaluation, treatment as well as prevention of hypertension, and eventually to improve adherence. Therefore, the large variety of antihypertensive drug options may require personalization for individual patients and a careful balance of antihypertensive efficacy, indications, and contraindications, in order to predict which drug will lower blood pressure most effectively in an individual subject with a good cost-effectiveness profile.

In this review, we discuss the fundamentals of personalized medicine for the management of chronic diseases such as hypertensive cardiovascular disease, focusing particularly on the possible applications of this new paradigm for the evaluation and treatment of hypertensive patients. The ultimate aim is to provide the physician with a precise tool to identify emerging biomarkers that will better address the therapeutic choice to improve the adherence to antihypertensive therapies and reach better blood pressure control in the individual patient and population at large.

Rationale of the personalized approach to hypertension: former approaches and new opportunities

The pathophysiology of hypertension is characterized by a complex interplay between susceptibility genes, physiological systems, and environmental factors, which develop over time [6]. Several methods of personalized treatment of hypertensive patients have been proposed and investigated. Personalized therapy in hypertension is conditioned by the recognition of a group of traits that may differentiate the response of individual patients. Thus, a modern approach to personalized treatment should consider the use of diagnostic and screening methods that take into account the distinctive molecular or risk profile of the individual patient in order to better identify the predisposition toward a disease or personalized management of the disease.

Stratifying patients based on renin profiling

The role of plasma renin activity (PRA) in the regulation of blood pressure and response to medications has been explored over many decades [58], and enormous effort was spent stratifying patients according to their renin, sodium, and volume profiling [59]. The approach using renin profile-guided treatment was characterized by equal or better blood pressure control compared with clinical decisions not informed by PRA [60], and represented the starting approach to physiological phenotyping that laid the foundation for hypertension precision medicine. However, the clinical utility of renin profiling has been questioned due to the influence of several confounders, such as sex, race, previous drug treatment, and assay issues, which might reduce the power of this approach in stratifying hypertensive patients. Nevertheless, the ratio between PRA and aldosterone is currently used to make a diagnosis of primary aldosteronism, although is not recommended by guidelines for widespread screening in hypertensive patients. Measuring circulating plasma renin in patients can also indicate the contribution of salt sensitivity to the disease. A low plasma renin can be considered a very specific marker for Na⁺ excess. This can address the therapeutic choice toward diuretics rather than other therapeutic options, particularly in individuals of African origin who have a salt-sensitive type of hypertension that is more responsive to diuretics or calcium channel blockers. In this regard, ethnicity can also be used to stratify treatment in an individualized perspective [61]. For instance, patients with Caucasian background younger than 55 years of age are more responsive to angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) reflecting an overactive renin angiotensin aldosterone system.

Former single-nucleotide polymorphism studies

Several genetic single-nucleotide polymorphisms (SNP) have been investigated as potential predictors of antihypertensive drug response, particularly in rare monogenic syndromes of hypertension secondary to the disruption of a specific pathway [62]. For instance, in Liddle’s syndrome (an autosomal dominant condition with hypertension associated with suppressed aldosterone and renin levels), a mutation in the epithelial Na⁺ channel gene induces increased rates of Na⁺ reabsorption, volume expansion, and hypertension. In this condition, specific inhibitors of the epithelial Na⁺ channel, such as amiloride or triamterene, could control elevated blood pressure values. Another example is familial hyperaldosteronism type 1, which is an autosomal dominant syndrome characterized by increased aldosterone secretion in response to pituitary adrenocorticotropic hormone (ACTH), which is responsible for hypertension. Individuals with this mutation respond to glucocorticoids, via the suppression of pituitary ACTH secretion [62]. A particular insertion/deletion polymorphism in the ACE gene was studied in a large population with hypertension, in order to examine the relationship with treatment response and coronary heart disease. The results demonstrated that there was no effect of insertion/deletion polymorphism on treatment response or coronary heart disease [63].
Introducing a new paradigm for cardiovascular prevention and therapy—systems biology

Any method used to date for the detection, evaluation, prevention, and treatment of hypertension or its target organ complications is unlikely to be equally successful in all individuals. Strategies tailored to the particular characteristics of individual patients are appealing and might lead to improved health of populations by optimizing outcomes for each individual patient [65,66].

In order to fully understand the rationale and hence the impact of precision medicine, it is important to know the fundamentals of systems biology [57,67]. Systems biology is the study of systems of biological components (i.e. molecules, cells, organisms, or entire species) via the computational and mathematical modeling of complex biological systems, and it is emerging as crucial to all areas of biology and medicine. Systems biology may be considered a ‘holistic’ approach to study the complexity of biological systems. From a biological perspective, organisms (living systems) are considered dynamic and complex, and consist of many integrated networks that communicate at different levels (genome, molecules, cells, and ultimately the entire organism which interacts with the environment) and their behaviors may be complicated to predict exclusively by analyzing the function of individual parts. In other words, a living organism may be considered a ‘network of networks’; thus systems biology focuses on the integrated analysis of the dynamic behaviors of these networks at different levels in order to formulate hypotheses for biological function and dynamical changes (Figure 1). This is different from traditional approaches to the study of living systems, which usually focus on a single scale with a limited understanding of the system. Fundamental to systems biology is the development and availability of modern high-throughput technology such as genomics, proteomics, metabolomics, bioinformatics, and computational models. These provide insights into new pathways and networks between systems, capture real-time molecular phenotypes, drive innovation in biology-based technology and computation in order to

Figure 1. Systems biology integrated network
Omnics data contribute to find biomarkers of the disease that contribute to clinical decision-making and may induce new hypothesis and biological questions to be tested.
discover new biomarkers for disease, which allow the detection of network perturbations foreshadowing the actual development of clinical symptoms, and eventually enable patient stratification on the basis of their individual genetic and molecular profiles (Figure 1). Moreover, this approach may help to understand the determinants of responses to treatments and individualize more specific and personalized targets for therapies by distinguishing in advance those patients that are most likely to benefit from a given drug from those who will suffer side effects (Figure 1). In other words, personalized medicine can be considered as an extension of traditional approaches to the understanding and management of disease, and incorporates individual genetic, molecular, and environmental variability by using in vitro diagnostics or imaging technologies (i.e. electroencephalography, electrocardiography, or diagnostic imaging tools) in order to develop accurate and reliable diagnostic tools and predictive biomarkers for the assessment of the patient’s individual characteristics (Figure 1). Thus, the new paradigm is shifting from the study of the ‘average’ cell to the ‘discrete’ cell-subtype in a cell population, as well as from ‘the average’ patient in a global population, to the evaluation of the unique characteristics of the individual patient. Compared with the traditional ‘trial-and-error’ approach to disease treatment, precision medicine, using tools that are more precise, may ensure simplification and speeding up of the diagnostic and decision-making processes and lead to more successful outcomes. Numerous molecular screening strategies have previously been developed for the risk stratification of individuals in order to develop markers capable of detecting the disease at the early phase of its development and to facilitate targeted strategies to prevent pathological complications [61,65,66-68]. For instance, in cancer research, considerable effort is currently spent on identifying the specific molecular markers in a cluster of malignant cells in order to develop specific treatments [69]. Current cardiology practice also relies on a variety of biomarkers, imaging, and clinical information for primary and secondary prevention of cardiovascular diseases, although those markers are not highly personalized. On the other hand, genetic tests and modern transcriptomic, proteomic, and metabolomic methodologies are able to acquire and give information related to the individual and environmental interactions, and may be extremely useful in identifying molecular fingerprints for a personalized approach to guide therapeutic decisions for cardiovascular patients in general and hypertensive patients in particular [66-70].

One important aspect of systems biology, and therefore of precision medicine, is data mining, taking into account the massive amount of data generated with current high-throughput technologies [65,66,71] (Figure 1). In order to explore and clinically interpret the complex interactions within the networks that result in individual phenotypes, the availability of advanced computational and analytical techniques, interoperable devices, and the development of informatic systems for the analysis and storage of the big data pool of ‘omics’ (genome sequences and molecular information) in open-to-public databases is crucial [72]. A central role for this task could be played by physicians that can mine data with appropriate algorithms in order to make open-to-public databases that could help data-driven medical decisions (Figure 2). In this process, individual patients also become central stakeholders who contribute to the collection of data by actively participating in shared decision-making (Figure 2). This novel approach could allow better patient monitoring and treatment even outside clinics. Therefore, more people can be treated in their home environment, improving their lifestyle and quality of life. Thus, ‘omics’ technologies have the potential to transform medicine from traditional symptom-oriented and treatment toward data-driven disease prevention, early diagnostics, and individualized treatment. There are different examples of the use of currently available high-throughput databases of genome-wide association data obtained from individuals at cardiovascular risk [73,74,75]. For instance, candidate genes for type 2 diabetes (including CD44 as the top candidate gene) have been identified by combining the results of 130 functional microarray experiments for this disease [74]. Moreover, it has been reported that risk alleles for diabetes were unequally distributed across different human populations, with the risk higher in African populations, by analyzing data of 2510 individuals from 74 populations [75].

Hence, decisions in precision medicine are based on information that integrates data from clinical research, systems biology, and laboratory tests (i.e. molecular and ‘omics’ data), imaging findings, and electronic health records (Figure 2). In this regard, healthcare will become a more dynamic and integrated system, in which the fulfillment of personalized medicine will involve a broad community working together in order to improve patient care by connecting new ideas and inputs in science and technology. As a result, this could improve compliance and clinical outcome, particularly in cardiovascular patients.

**Integrative ‘omics’ as predictive, diagnostic, and prognostic biomarkers in disease-oriented cardiovascular medicine**

Currently, molecular disease analyses using a large-scale approach are being employed by some clinicians and pathologists [61,65,66,70] in order to highlight personalized disease susceptibility assessment and thus, patients can be treated according to their own genetic and molecular phenotype.
Whole genome sequencing (WGS) and whole exome sequencing (WES), the single-base analysis of a genome-exome, have become largely available and affordable for genomic studies [61,65,66,70]. Moreover, the availability of next-generation sequencing [76], as well as proteomics [77], metabolomics [78], transcriptomics, and epigenetics [79] stimulated interest in the application of other ‘omics’ to study chronic diseases [80] from an individual and integrated perspective. The network of genetic variants that account for the biological differences between individuals may physically and functionally connect the molecular elements in the system at different levels (i.e. metabolic and/or environmental level) to produce a highly individualized disease phenotype. This novel clinical integrated approach can help to identify perturbations in the system derived from these interactions and to discover specific therapeutic targets that can modulate the key junctions in the integrated networks to more precisely and safely restore the homeostasis of the system and the phenotype [81-83].

**Genomics and pharmacogenomics**

Analyzing the genome can be used to discover pathophysiological pathways, evaluate the individual risk for a given person compared with the population at risk (also taking into account the same group of ethnicity, age, and gender), and may suggest potential targets for more individualized therapies. Whole genome sequence revealed variants for both high-penetrance Mendelian disorders [84,85], as well as, complex, chronic diseases including hypertension [86]. Chronic disease-related research has gained significant benefit from WGS and WES technologies [66]. Advanced application of this approach is the use of next-generation WGS and computational genomics in the context of family pedigrees, examining the diversity of the human genome over the entirety of the human population. Family genomics is a powerful and precise method for identifying sequencing errors, disease-causing gene mutations, and genetic relationships between individuals, as has been applied to identify high-risk genes for diseases such as familial thrombophilia, obesity, and psoriasis [87].

Currently, GWAS studies have reported the association of more than 7000 SNP with over 700 complex traits [88]. The study of complex traits may include a variety of chronic diseases ranging from cancers to other chronic complex diseases including diabetes, hypertension, and cardiovascular diseases. A large number of cancer genomes have been sequenced, for different types of tumors [89-100], which may help to understand the susceptibility to the disease as well as better addressing treatment. In addition, for cardiovascular disease, several studies have been performed for
genetic associations in individual patients in order to test the risk of developing the disease. For instance, genomic analysis for the risk of cardiovascular diseases was estimated in healthy subjects demonstrating increased probability of risk for myocardial infarction and coronary artery disease [101]. In patients with a family history of vascular disease and early sudden death, genetic variants associated with heart-related morbidities as well as drug response were identified [102]. This information could facilitate future healthcare for an individual patient. In hypertension research, GWAS studies have discovered approximately 63 loci influencing blood pressure, although these variants are responsible for less than 1% of variation in blood pressure in the general population [61,88]. In individuals with hypertension in the Framingham Heart Study population, genetic variants that led to severe hypertensive phenotypes or even protection against hypertension were identified [103]. Some of these common variants are correlated to pathways that can be targeted for individualized therapy. Indeed, it is known that the same drugs may have different effects on different individuals due to their personal genomic background and living habits [104,105], as genetic polymorphisms may partially account for interindividual variability and lack of consistent responsiveness to antihypertensive drugs.

The identification of key enzymes that may play a role in variation in drug metabolism and response has provided the basis for pharmacogenomics. This critically important area of personalized medicine specifically focuses on the variations of DNA and RNA characteristics related to individual drug response [104,105], and may suggest tailored antihypertensive therapeutic options in order to reduce side effects and ultimately healthcare costs [88].

Several hypertension studies have focused on genetic association with the effect of different antihypertensive drugs, particularly diuretics and β-blockers. For instance, a previous GWAS study identified a single SNP in the upstream end of the uromodulin gene (UMOD) associated with blood pressure regulation as well as hypertension [106]. The UMOD gene is expressed in the kidney at the thick ascending limb of the loop of Henle and may interact with the co-transporter 2 (NKCC2) channel modulating the reabsorption of filtered Na⁺. Thus, in patients carrying this mutation, furosemide could be the first-line therapeutic choice since it is an inhibitor of NKCC2. Yet genotype-directed trials are required to determine whether the UMOD variant could individualize patients that potentially gain benefit from loop diuretic treatment, particularly in the setting of uncontrolled hypertension. Furthermore, the genetic polymorphism rs149601G>A of the NEDD4L (which encodes the NEDD4 protein that controls the cell surface expression of different sodium transporters including ENaC and NKCC2) has been associated with reduced ENaC expression, sodium retention, and hypertension with lower plasma renin activity [107-110]. Thus, patients carrying this mutation could better respond to a thiazide diuretic as shown in different clinical studies [111-113]. In the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study only hydrochlorothiazide showed a greater blood pressure lowering effect in patients with GG alleles [112]. In the Nordic Diltiazem (NORDIL) study, carriers of the G allele exhibited a better blood pressure lowering effect and better outcome in response to the thiazide diuretic/β-blocker combination treatment than patients with AA genotype [111]. Consistently, in the International Verapamil SR Trandolapril Study (INVEST) patients who carried the G allele showed cardiovascular risk if not treated with a thiazide diuretic [112]. Another GWAS study in over 60,000 subjects identified a polymorphism of ADRB1 associated with hypertension and the response to β-blockers. This gene encodes the β-1 adrenergic receptor for the catecholamines, and the Arg389 and Ser49/Arg389 haplotypes have been associated with greater response to β-blockers [114-117]. Interestingly, in the INVEST study, patients with these haplotypes presented increased cardiovascular risk on verapamil therapy alone, the risk was offset by using β-blockers. Nonetheless, future research needs to better define whether these polymorphisms could be used to guide therapeutic decision in hypertensive subjects.

The advances in epigenomics have provided another strategy for defining subgroups of hypertensive patients who might benefit from specific therapies. For instance, aldosterone may target the epigenetically modified sodium channel epithelial 1x subunit (SCNN1A), which has been demonstrated to present hypermethylation of histone H3 at lysine 79 (H3K79) at subregions of the promoter in some individuals [118]. The effort of identifying functional genetic and epigenetic markers is extremely important to identify a new category of mechanism-based genetic biomarkers that can facilitate the management of hypertension [119] from an individualized perspective.

In spite of these advances, there is still no ideal biomarker available with a high predictive accuracy for the response to antihypertensive therapies. Therefore, prospective randomized studies are required in order to detect biomarkers and demonstrate a clear clinical utility of the genomic approach [120-122], in terms of improved outcomes. Recently, this approach was employed in a large Chinese population in which 11 biomarkers were used to predict the development of hypertension with some success and accuracy [123]. The GENRES randomized, placebo-controlled, cross-over trial [121] has also suggested a possible relationship between nephrosis (NPNS) gene variants and response to the angiotensin receptor blocker losartan, as well as between PRKCA (which encodes protein kinase Cα) gene variants and blood pressure response to hydrochlorothiazide.
Moreover, experimental studies have demonstrated that a p38 mitogen-activated protein kinase (MAPK) inhibitor suppressed the markers of end-organ damage, osteopontin, and plasminogen activator inhibitor 1, in a rat model of hypertension and correlated with improved end-organ function [124].

On the other hand, genetic studies present some limitations [125] related to the fact that they typically only analyze a small fraction of the genome, in addition, gene–gene interactions are largely neglected. Moreover, genomic information alone is not usually adequate to predict disease onset, and other factors such as environment are expected to play a critical role in the pathophysiological process [126,127], particularly for alterations in blood pressure regulation.

Other personalized ‘omics’ in precision medicine

Other ‘omics’ technologies might also have an impact on personalized medicine providing increasingly detailed and individualized characterization of hypertension subgroups. Among them, proteomics, transcriptomics, and metabolomics may contribute to defining the fingerprints and markers that constitute the foundation for precision medicine. The profiles of the transcriptome, proteome, and metabolome are more precise indicators of the real-time phenotype, compared with genomic sequences alone; therefore, collecting this ‘omics’ information in an integrated manner would allow monitoring the physiological state of the individual patient in a more complete way, which could complement the systems biology approach, particularly for a multifactorial and complex disease such as hypertension.

Proteomics is defined as the characterization and quantification of proteins in an organism. The information to build every protein in an organism is contained in the DNA, but not every protein is produced at once or in the same amount. The current use of mass spectrometry has enabled great advancements in the proteomic analysis of biological macromolecules with high sensitivity and accuracy [128,129]. With this technology it is possible to quantify a large amount of proteins in a single sample, while simultaneously detecting the expression of mutations and editing events in the human proteome [119], as well as profiling of the phosphoproteome [130]. High-throughput sequencing technologies have also enabled whole transcriptome (cDNA) sequencing [131], which is a powerful tool for disease-related studies, as it can reflect the actual gene activity by also detecting splicing isoforms [132]. Combining such information with genomic information may be valuable in the treatment of chronic diseases, including hypertension.

Profiling small molecules (i.e. metabolome) in a comprehensive and quantitative manner in biological fluids also provides an analysis of multiple biological pathways [70,133]. Since the metabolome reflects the metabolism as well as the real-time energy status of the living organism, it is expected that certain metabolome profiles may provide mechanistic insight and might be associated with different diseases [134]. Particularly fascinating is that it could result in the metabolomic analysis of hypertension, since hypertension is often associated with alteration of metabolic pathways. Therefore, metabolomic profiles are an important aspect for personalized medicine [135,136], predominantly for cardiovascular disease. In particular, it has been shown that the atenolol-induced changes in the metabolome are dependent on race and genotype, which can help to explain the differential metabolomics signature of response to atenolol and the differential response in blood pressure to β-blockers [137].

Challenges, opportunities, and future directions

Precision medicine is an emerging and growing field, and will probably be of major importance in the future. Growth in this area has been facilitated by the development of systems biology and high-throughput technologies. Undoubtedly, the increasing knowledge and interpretation of personalized ‘omics’ data will enhance our understanding of physiological events during health and disease, and promote personalized diagnosis and treatment. Using this approach, precision medicine aims to reduce the burden of disease by targeting prevention and treatment more effectively through the integration of inputs from multiple data sources. Moreover, individualized medicine might also decrease healthcare costs and prevent adverse events by improving the ability to select the right therapy at the right time for an individual patient.

However, personalization will become more difficult in hypertension since it needs to integrate biological, non-biological, and environmental factors in decision-making, much more than other conditions such as cancer therapy where genomic factors may play a central role. In complex diseases, such as hypertension, peripheral components of the biological network would be more likely to contribute to the disease than genetic determinants, which are also more probabilistic than deterministic for the development of the disease. Thus, in hypertension, genetic or molecular markers cannot be considered isolated from other reasons for uncontrolled hypertension, which include salt sensitivity, excessive alcohol consumption, sleep apnea, renal artery stenosis, and comorbidities such as obesity, diabetes,
Characteristics of Basket trial, Umbrella trial, and N-of-1 trial.

and chronic kidney disease. Furthermore, the intraindividual variability in blood pressure levels may also have an impact on the determination of response to drugs. Finally, the impact of environment and personal choices also affects patient behavior and treatment outcomes.

Thus, future approaches to the personalization of hypertension treatment will possibly focus less on the DNA sequence and more on variables that can change over time. The fields of epigenomics, metabolomics, proteomics, and transcriptomics are likely to yield data useful in personalizing the treatment of hypertension. This combined information not only determines the genetic susceptibility of the person, but also monitors his/her real-time physiological states [67].

Personalized medicine, using ‘omics’ approaches, relies on the growing development of technology for biological research, which is now affordable due to the rapid drop in technology costs. A challenge that should not be overlooked in this new era of complex data regards storage and the analytical aspect of the ‘omics’ data, and as such it will be critical for biologists, clinicians, bioinformaticians, and data scientists to work together in a truly integrated manner to ensure the continued improvement of this field.

However, the significance of any specific approach to personalized medicine still needs to be tested. Therefore, any proposed personalization method would theoretically need a clinical trial to demonstrate benefit above current guideline-based therapy, although less rigorous evidence might be acceptable [138]. In addition to traditional types of clinical trials, such as randomized, cross-over, double-blind etc., several new approaches for phase I clinical trials have been developed, such as Basket and Umbrella trials, as well as the N-of-1 trial that might better account for variability between patients [139-142] (Figure 3). In particular, in Basket Trials, drugs are tested based on their mode of action and all participants included in the trial have a common contributing or facilitating factor, such as an abnormal protein or metabolic pathway, which may be the target of the drug. In Umbrella Trials, the opposite strategy is followed. Participants present the same clinical diagnosis but specific genetic markers or other factors may vary. Drugs are tested according to individual profiles, therefore in one trial several different drugs may be tested for the same disease, and adaptive trial protocols that allow modifications to interventions based on participant responses for a subset of individual participants are allowed while the trial is ongoing. However, these studies are not considered sufficiently personalized. Therefore, a trial centered more on individual (such as N-of-1 trials) than on ‘average responses to therapy’ is required. N-of-1 trials have already been utilized as a matter of necessity for rare diseases. In this type
of trial, different treatments (including placebo) are evaluated in one patient over a period of time. Although the N-of-1 trial may require elaborate study design and the results may not be easily extrapolated to other patients, it can provide useful medical information for subsets of patients in the general population. A detailed discussion on clinical trials informed by biomarkers has recently been reviewed by Antman and Loscalzo [65], and a critical discussion on the new types of clinical trials has been reviewed by Schork [139]. It is now timely to extend clinical trials beyond the classical clinical approaches, by considering methods to address personalized medicine. This requires specialized centers for the application of high-throughput system biology technology as well as resources and infrastructure to collect integrated computational data. This implies that future healthcare systems will need the integration, analysis, and representation of data to enable data visualization and a more precise selection of therapeutic regimens [143].

A discussion that warrants some consideration relates to the economics and cost-benefits associated with personalized medicine. As the field evolves and as 'large data' results become available, comprehensive health economic analysis will be crucial. To date, we are still in the infancy phase of personalized medicine and hence economic analysis is based on predictions and theoretical knowledge. If personalized medicine does lead to the 'right medicine for the right patient at the right time' then health management and associated costs should be less than the current state, where the economic burden of treating cardiovascular disease is enormous. It should also be highlighted that the costs of ‘high-throughput technologies’ to profile individual patients have been markedly reduced over the past decade and hence global expenses to invest in this new approach should be more affordable, would be worthy, and might contribute to reducing general healthcare costs, since the global cardiovascular risk could be controlled better in numerous patients in primary and/or secondary prevention, and, optimistically, personalized medicine would contribute greatly to reducing the burden of cardiovascular events which is currently still high and contributes substantially to healthcare expenses.

Furthermore, the new approach toward personalized medicine involves the patient as a central and active participant of the complex network. Education and training for healthcare providers and patients are essential to prepare for the next phase of modern medicine so that the tremendous potential of personalized medicine, for the individual patient and ultimately the population at large, can be realized.

Author Contribution
All the authors have contributed substantially to this work.

Funding
C.S. was supported by a grant from Fondazione Roma [grant number NCDS-2013-00000345] and a grant from Italian Ministry of Education, University and Research [grant number PRIN-2015ZTT5KB_003]; R.M.T. was supported by the British Heart Foundation [grant number CH/4/29762].

Competing Interests
The authors declare that there are no competing interests associated with the manuscript.

Abbreviations
ACEI, angiotensin-converting enzyme inhibitor; ACTH, adrenocorticotropic hormone; ARB, angiotensin receptor blocker; GWAS, genome-wide association; MAPK, mitogen-activated protein kinase; SNP, single-nucleotide polymorphisms; WES, whole exome sequencing; WGS, whole genome sequencing.

References
1 Hajjar, I. and Kotchen, T.A. (2003) Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. J. Am. Med. Assoc. 290, 199–206
2 WHO (2013) A Global Brief on Hypertension, World Health Organization, Geneva
3 Lim, S.S., Vos, T., Flaxman, A.D., Danaei, G., Shibuya, K., Adair-Rohani, H. et al. (2012) A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2224–2260
4 Lewington, S., Clarke, R., Qizilbash, N., Petro, R. and Collins, C. (2002) Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360, 1903–1913
5 Vasan, R.S., Larson, M.G., Leip, E.P., Evans, J.C., O’Donnell, C.J., Kannel, W.B. et al. (2001) Impact of high-normal blood pressure on the risk of cardiovascular disease. N. Engl. J. Med. 345, 1291–1297
6 Mozaffarian, D., Benjamin, E.J., Go, A.S., Arnett, D.K., Blaha, M.J., Cushman, M. et al. (2016) Heart disease and stroke statistics – 2016 update: a report from the American Heart Association. Circulation 133, 447–454
34 Weber, M.A., Schiffinr, E.L., White, W.B., Mann, S., Lindholm, L.H., Kenerson, J.G. et al. (2014) Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J. Hypertens. 32, 3–15
35 McNamur, R.J., Cauffield, M. and Williams, B. (2012) National Institute for Health and Clinical Excellence. NICE hypertension guideline 2011: evidence based evolution. Br. Med. J. 344, e181
36 James, P.A., Oparil, S., Carter, B.L., Cushman, W.C., Dennison-Himmelfarb, C., Handler, J. et al. (2014) 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). J. Am. Med. Assoc. 311, 507–520
37 Stephan, D., Gaetter, S. and Cordeanu, E.M. (2015) A critical appraisal of the guidelines from France, the UK, Europe and the USA for the management of hypertension in adults. Arch. Cardiovasc. Dis. 108, 453–459
38 Daskalopoulou, S.S., Rabi, D.M., Zarnke, K.B., Dasgupta, K., Nerenberg, K., Cloutier, L. et al. (2015) The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can. J. Cardiol. 31, 549–568
39 Blacher, J., Halimi, J.M., Hanon, O., Mourad, J.J., Pathak, A., Schnebert, B. et al. (2014) French Society of Hypertension. Management of hypertension in adults: the 2013 French Society of Hypertension guidelines. Fundam. Clin. Pharmacol. 28, 1–9
40 Patel, A., MacMahon, S., Chalmers, J., Neal, B., Woodward, M., Billot, L. et al. (2007) Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370, 829–840
41 PROGRESS Collaborative Group (2001) Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 358, 1033–1041
42 Yusuf, S., Sleight, P., Pogue, J., Bosch, J., Davies, R. and Dagenais, G. (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med. 342, 145–153
43 Wright, J.T., Williamson, J.D., Whelton, P.K., Snyder, J.K., Sink, K.M., Rocco, M.V. et al. (2015) A randomized trial of intensive versus standard blood-pressure control. N. Engl. J. Med. 373, 2103–2116
44 Wright, Jr, J.T., Fine, L.J., Lackland, D.T., Ogedegbe, G. and Himmelfarb, C.R. (2014) Evidence supporting a systolic blood pressure goal of less than 150 mm Hg in patients aged 60 years or older: the minority view. Ann. Intern. Med. 160, 499–503
45 Law, M.R., Morris, J.K. and Wald, N.J. (2009) Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 17 randomised trials in the context of expectations from prospective epidemiological studies. Br. Med. J. 338, b1665
46 Chobanian, A.V. (2009) Shattuck Lecture. The hypertension paradox—more uncontrolled disease despite improved therapy. N. Engl. J. Med. 361, 878–887
47 Chobanian, A.V. (2015) Time to reassess blood-pressure goals. N. Engl. J. Med. 373, 2093–2095
48 Borghi, C. and Rossi, F (2016) Role of the renin-angiotensin-aldosterone system and its pharmacological inhibitors in cardiovascular diseases: complex and critical issues. High Blood Press. Cardiovasc. Prev. 23, 65
49 Tocci, G., Nati, G., Crisceli, C., Parretti, D., Lapi, F., Ferrucci, A. et al. (2016) Prevalence and control of hypertension in different macro-areas in Italy: analysis of a large database by the general practice. High Blood Press. Cardiovasc. Prev. 23, 387–393
50 Wang, Y. and Wang, Q.J. (2004) The prevalence of prehypertension and hypertension among US adults according to the new joint national committee guidelines: new challenges of the old problem. Arch. Intern. Med. 164, 2126–2134
51 Tocci, G., Ferrucci, A., Pontremoli, R., Feni, C., Rossi, A.E., Morganti, A. et al. (2015) Blood pressure levels and control in Italy: comprehensive analysis of clinical data from 2000-2005 and 2005-2011 hypertension surveys. J. Hum. Hypertens. 29, 696–701
52 Mazzaglia, G., Ambrosioni, E., Alacqua, M., Filippi, A., Sessa, E., Immordino, V. et al. (2009) Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation 120, 1598–1605
53 Tomaszewski, M., White, C., Patel, P., Mascia, N., Damani, R., Hepworth, J. et al. (2014) High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis. Heart 100, 855–861
54 Jung, O., Gechter, J.L., Wunder, C., Paulke, A., Bartel, C., Geiger, H. et al. (2013) Resistant hypertension? Assessment of adherence by toxicological urine analysis. J. Hypertens. 31, 766–774
55 Snyderman, R. and Drake, C.D. (2015) Personalized health care: unlocking the potential of genomic and precision medicine. J. Precision Med. 1, 38–41
56 Naylor, S. (2015) What's in a name? The evolution of 'P-Medicine'. J. Precision Med. 1, 15–29
57 Loscalzo, J. and Barabasi, A.L. (2011) Systems biology and the future of medicine. Wiley Interdiscip. Rev. Syst. Biol. Med. 3, 619–627
58 Laragh, J.H. and Sealey, J.E. (2011) The plasma renin test reveals the contribution of body sodium-volume content (V) and renin-angiotensin (R) vasocostriction to long-term blood pressure. Am. J. Hypertens. 24, 1164–1180
59 Laragh, J.H. (1973) Vasoconstriction-volume analysis for understanding and treating hypertension: the use of renin and aldosterone profiles. Am. J. Med. 55, 261–274
60 Egan, B.M., Basile, J.N., Rehman, S.U., Davis, P.B., Grob, C.H., Riehe, J.F. et al. (2009) Plasma renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial. Am. J. Hypertens. 22, 792–801
61 Currie, G. and Delles, C. (2016) Use of biomarkers in the evaluation and treatment of hypertensive patients. Curr. Hypertens. Rep. 18, 54
62 Padmanabhan, S., Cauffield, M. and Dominiczak, A.F. (2015) Genetic and molecular aspects of hypertension. Circ. Res. 116, 937–959
63 Arnett, D.K., Davis, B.R., Ford, C.E., Boerwinkle, E., Leidiender-Foster, C., Miller, M.B. et al. (2005) Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study. Circulation 111, 3374–3383
85 Kaufman, S. (1999) Replication validity of genetic association studies. *Nat. Genet.* **29**, 306–309

86 Antman, E.M. and Loscalzo, J. (2016) Precision medicine in cardiology. *Nat. Rev. Cardiol.* **13**, 591–602

87 Chen, R. and Snyder, M. (2012) Promise of personalized omics to precision medicine. *Curr. Opin. Pharmacol.* **12**, 623–628

88 Louridas, G.E. and Lourida, K.G. (2017) Conceptual foundations of systems biology explaining complex cardiac diseases. *Healthcare (Basel)* **5**, pii:E10, https://doi.org/10.3390/healthcare5010010

89 Byrd, J.B. (2016) Personalized medicine and treatment approaches in hypertension: current perspectives. *Integr. Blood Press. Control* **9**, 59–67

90 Roychowdhury, S. and Chinnaiyan, A.M. (2016) Translating cancer genomes and transcriptomes for precision oncology. *CA Cancer J. Clin.* **66**, 75–88

91 Dona, A.C., Coffey, S. and Figtree, G. (2016) Translational and emerging clinical applications of metabolomics in cardiovascular disease diagnosis and treatment. *Eur. J. Prev. Cardiol.* **23**, 1578–1589

92 Nekrutenko, A. and Taylor, J. (2012) Next-generation sequencing data interpretation: enhancing reproducibility and accessibility. *Nat. Rev. Genet.* **13**, 667–672

93 Ferialdi, G.H., Capriotti, E., Daneshjou, R., Karczewski, K.J. and Altman, R.B. (2011) Bioinformatics challenges for personalized medicine. *Bioinformatics* **27**, 1741–1748

94 Roberts, N.J., Vogeleit, J.T., Parmigiani, G., Kinzler, K.W., Vogelstein, B. and Velculescu, V.E. (2012) The predictive capacity of personal genome sequencing. *Sci. Transl. Med.* **4**, 133–158

95 Kodama, K., Horikoshi, M., Toda, K., Yamada, S., Haru, K., Irie, J. et al. (2012) Expression-based genome-wide association study links the receptor CD44 in adipose tissue with type 2 diabetes. *Proc. Natl. Acad. Sci. U.S.A.* **109**, 7049–7054

96 Chen, R., Corona, E., Sikora, M., Dudley, J.T., Morgan, A.A., Moreno-Estrada, A. et al. (2012) Type 2 diabetes risk alleles demonstrate extreme directional differentiation among human populations, compared to other diseases. *PLoS Genet.* **8**, e1002621

97 Mogensen, J., van Tintelen, J.P., Fokstuen, S., Elliott, P., van Langen, I.M., Meder, B. et al. (2015) The current role of next-generation DNA sequencing in routine care of patients with hereditary cardiovascular conditions: a viewpoint paper of the European Society of Cardiology working group on myocardial and pericardial diseases and member of European Society of Human Genetics. *Eur. Heart J.* **36**, 1367–1370

98 Lindsay, M.L., Mayr, M., Gomes, A.V., Delles, C., Arrell, D.K., Murphy, A.M. et al. (2015) Transformative impact of proteomics on cardiovascular health and disease: a scientific statement of the American Heart Association. *Circulation* **132**, 852–872

99 Shah, S.H. and Newgard, C.B. (2015) Integrated metabolomics and genomics: system approach to biomarkers and mechanisms of cardiovascular disease. *Circ. Cardiovasc. Genet.* **8**, 410–419

100 Wende, A.R. (2016) Post translational modification of the cardiac proteome on diabetes and heart failure. *Proteomics: Clin. Appl.* **10**, 25–38

101 Fox, C.S., Hall, J.L., Arnett, D.K., Ashley, E.A., Delles, C., Engler, M.B. et al. (2015) Future translational application from the contemporary genomics era: a scientific statement from the American Heart Association. *Circulation* **131**, 1715–1736

102 Barabasi, A.L., Gulbahce, N. and Loscalzo, J. (2011) Network medicine: a network-based approach to human disease. *Nat. Rev. Genet.* **8**, 218–228

103 Walker, F.O. (2007) Huntington’s disease. *Lancet* **369**, 219–223

104 Kaufman, S. (1999) A model of human phenylalanine metabolism in normal subjects and in phenylketonuric patients. *Proc. Natl. Acad. Sci. U.S.A.* **96**, 3160–3164

105 Jostins, L. and Barrett, J.C. (2011) Genetic risk prediction in complex disease. *Hum. Mol. Genet.* **20**, R182–R188

106 Dewey, F.E., Chen, R., Cordero, S.P., Ormond, K.E., Caleshu, C., Karczewski, K.J. et al. (2011) Phased whole-genome genetic risk in a family quartet using a major allele reference sequence. *PLoS Genetics* **7**, e1002280

107 Cooper-Deloff, R.M. and Johnson, J.A. (2016) Hypertension pharmacogenomics: in search of personalized treatment approaches. *Nat. Rev. Nephrol.* **12**, 110–122

108 Schwartzentruber, J., Korshunov, A., Liu, X.Y., Jones, D.T., Pfaff, E., Jacob, K. et al. (2012) Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. *Nature* **482**, 226–231

109 Natraj, R., Mackay, A., Lambros, M.B., Weigelt, B., Wilkerson, P.M., Manie, E. et al. (2012) A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers. *J. Pathol.* **227**, 29–41

110 Yost, S.E., Smith, E.N., Schwab, R.B., Bao, L., Jung, H., Wang, X. et al. (2012) Identification of high-confidence somatic mutations in whole genome sequence of formalin-fixed breast cancer specimens. *Nucleic Acids Res.* **40**, e107

111 Puente, X.S., Pinyol, M., Quesada, V., Conde, L., Ordonez, G.R., Villamor, N. et al. (2011) Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. *Nature* **475**, 101–105

112 Totoki, Y., Tatsuno, K., Yamamoto, S., Aral, Y., Hosoda, F., Ishikawa, S. et al. (2011) High-resolution characterization of a hepatocellular carcinoma genome. *Nat. Genet.* **43**, 464–469

113 Pleasance, E.D., Cheetham, R.K., Stephens, P.J., McBride, D.J., Humphray, S.J., Greenman, C.D. et al. (2010) Comprehensive catalogue of somatic mutations from a human cancer genome. *Nature* **463**, 191–196

114 Bell, D., Berchuck, A., Birrer, M., Chien, J., Cramer, D., Yao, F. et al. (2011) Integrated genomic analyses of ovarian carcinoma. *Nature* **474**, 609–615

115 Pleasance, E.D., Stephens, P.J., O’Meara, S., McBride, D.J., Meynert, A., Jones, D. et al. (2010) A small-cell lung cancer genome with complex signatures of tobacco exposure. *Nature* **463**, 184–190

116 Rausch, T., Jones, D.T., Zapatka, M., Stutz, A.M., Zichner, T., Weischenfeldt, J. et al. (2012) Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. *Cell* **148**, 59–71

117 Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A.A., Kim, S. et al. (2012) The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. *Nature* **483**, 603–607
99 Xu, X., Hou, Y., Yin, X., Bao, L., Tang, A., Song, L. et al. (2012) Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor. Cell 148, 886–895

100 Hou, Y., Song, L., Zhu, P., Zhang, B., Tao, Y., Xu, X. et al. (2012) Single-cell exome sequencing and multigene evolution of a JAK2-negative myeloproliferative neoplasm. Cell 148, 873–885

101 Ashley, E.A., Butte, A.J., Wheeler, M.T., Chen, R., Klein, T.E., Dewey, F.E. et al. (2010) Clinical assessment incorporating a personal genome. Lancet 375, 1525–1535

102 Pushkar, D., Neff, N.F. and Quake, S.R. (2009) Single-molecule sequencing of an individual human genome. Nat. Biotechnol. 27, 847–850

103 Ji, W., Foo, J.N., O’Roak, B.J., Zhao, H., Larson, M.G., Simon, D.B. et al. (2008) Rare independent mutations in renal salt handling genes contribute to blood pressure variation. Nat. Genet. 40, 592–599

104 Antman, E., Weiss, S. and Loscalzo, J. (2012) Systems pharmacology, pharmacogenetics, and clinical trial design in network medicine. Wiley Interdiscip. Rev. Syst. Biol. Med. 4, 367–383

105 Ma, Q. and Lu, A.Y. (2011) Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol. Rev. 63, 437–459

106 Padmanabhan, S., Melander, O., Johnson, T., Di Blassio, A.M., Lee, W.K., Gentilini, D. et al. (2010) Genome-wide association study of blood pressure extremes identifies variant near UMOD associated with hypertension. PLoS Genet. 6, e1001177

107 Russo, C.J., Melista, E., Cui, J., DeStefano, A.L., Bakris, G.L., Manolis, A.J. et al. (2005) Association of NEDD4L ubiquitin ligase with essential hypertension. Hypertension 46, 488–491

108 Luo, F., Wang, Y., Wang, X., Sun, K., Zhou, X. and Hui, R. (2009) A functional variant of NEDD4L is associated with hypertension, antihypertensive response, and orthostatic hypotension. Hypertension 54, 796–801

109 Dahlberg, J., Sjögren, M., Hedblad, B., Engström, G. and Melander, O. (2014) Genetic variation in NEDD4L, an epithelial sodium channel regulator, is associated with cardiovascular disease and cardiovascular death. J. Hypertens. 32, 294–299

110 Dahlberg, J., Nilsson, L.O., von Wossm, F. and Melander, O. (2007) Polymorphism in NEDD4L is associated with increased salt sensitivity, reduced levels of P-renin and increased levels of NT-proANP. PLoS One 2, e432

111 Svensson-Farbom, P., Wahlstrander, B., Almgren, P., Dahlberg, J., Fava, C., Kjeldsen, S. et al. (2011) A functional variant of the NEDD4L gene is associated with beneficial treatment response with β-blockers and diuretics in hypertensive patients. J. Hypertens. 29, 388–395

112 McDonough, C.W., Burbage, S.E., Duarte, J.D., Gong, Y., Langae, T.Y., Turner, S.T. et al. (2013) Association of variants in NEDD4L with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics. J. Hypertens. 31, 698–704

113 Johnson, J.A. and Liggett, S.B. (2011) Cardiovascular pharmacogenomics of adrenergic receptor signaling: clinical implications and future directions. Clin. Pharmacol. Ther. 89, 366–378

114 Johnson, J.A., Zineh, I., Puckett, B.J., McGorray, S.P., Yarandi, H.N. and Pauly, D.F. (2003) β1-adrenergic receptor polymorphism and antihypertensive response to metoprolol. Clin. Pharmacol. Ther. 74, 44–52

115 Liu, J., Liu, Z.O., Yu, B.N., Xu, F.H., Mo, W., Zhou, G. et al. (2006) β1-adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension. Clin. Pharmacol. Ther. 80, 23–32

116 Wu, D., Li, G., Deng, M., Song, W., Huang, X., Guo, X. et al. (2015) Associations between ADRB1 and CYP2D6 gene polymorphisms and the response to β-blocker therapy in hypertension. J. Int. Med. Res. 43, 424–434

117 Si, D., Wang, J., Xu, Y., Chen, X., Zhang, M. and Zhou, H. (2014) Association of common polymorphisms in β1-adrenergic receptor with antihypertensive treatment response to carvedilol. J. Cardiovasc. Pharmacol. 64, 306–309

118 Zhang, W. (2015) Epigenetics of epithelial Na+ channel-dependent sodium uptake and blood pressure regulation. World J. Nephrol. 4, 363–366

119 El Shami, S. and Visvikis-Siest, S. (2012) Genetic biomarkers of hypertension and future challenges integrating epigenomics. Clin. Chim. Acta 414, 259–265

120 Arnett, D.K. and Claas, S.A. (2009) Pharmacogenetics of antihypertensive treatment: detailing disciplinary dissonance. Pharmacogenomics 10, 1295–1307

121 Hiltunen, T.P., Donner, K.M., Sarin, A.P., Saarela, J., Ripatti, S., Chapman, A.B. et al. (2015) Pharmacogenomics of hypertension: a genome-wide, placebo-controlled cross-over study, using four classes of antihypertensive drugs. J. Am. Heart Assoc. 4, e001521

122 Turner, S.T., Boerink, E., O’Connell, J.R., Bailey, K.R., Gong, Y., Chapman, A.B. et al. (2013) Genomic association analysis of common variants influencing antihypertensive response to hydrochlorothiazide. Hypertension 62, 391–397

123 Zhang, W., Wang, L., Chen, Y., Tang, F., Xue, F. and Zhang, C. (2015) Identification of hypertension predictors and application to hypertension prediction in an urban Han Chinese population: a longitudinal study. 2005-2010. Prev. Chronic Dis. 12, E184

124 Nerurkar, S.S., Olzinski, A.R., Frazier, K.S., Mirabile, R.C., O’Brien, S.P., Jing, J. et al. (2007) P38 MAPK inhibitors suppress biomarkers of hypertension end-organ damage, osteopontin and plasminogen activator inhibitor-1. Biomarkers 12, 87–112

125 Su, M.W., Tung, K.Y., Liang, P.H., Tsai, C.H., Kuo, N.W. and Lee, Y.L. (2012) Gene-gene and gene-environmental interactions of childhood asthma: a multifactor dimension reduction approach. PLoS 7, e30694

126 Chakravarthi, A. (2011) Genomics is not enough. Science 334, 15

127 Cravatt, B.F., Simon, G.M. and Yates, III, J.R. (2007) The biological impact of mass-spectrometry-based proteomics. Nature 450, 991–1000

128 Wu, L. and Han, D.K. (2006) Overcoming the dynamic range problem in mass spectrometry-based shogun proteomics. Expert Rev. Proteomics 3, 611–619

129 Ruppen-Canas, I., Lopez-Casas, P.P., Garcia, F., Ximenez-Embun, P., Munoz, M., Morelli, M.P. et al. (2012) An improved quantitative mass spectrometry analysis of tumor specific mutant proteins at high sensitivity. Proteomics 12, 1319–1327

130 Villen, J. and Gygi, S.P. (2008) The SCX/IMAC enrichment approach for global phosphorylation analysis by mass spectrometry. Nat. Protoc. 3, 1630–1638
131 Nagalakshmi, U., Wang, Z., Waern, K., Shou, C., Raha, D., Gerstein, M. et al. (2008) The transcriptional landscape of the yeast genome defined by RNA sequencing. Science **320**, 1344–1349

132 Wang, Z., Gerstein, M. and Snyder, M. (2009) RNA-Seq: a revolutionary tool for transcriptomics. Nat. Rev. Genet. **10**, 57–63

133 Brindle, J., Antti, H., Holmes, E., Tranter, G., Nicholson, J.K., Bethell, H.W. et al. (2002) Rapid and non invasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabolomics. Nat. Med. **8**, 1439–1444

134 Griffin, J.L. and Shockcor, J.P. (2004) Metabolic profiles of cancer cells. Nat. Rev. Cancer **4**, 551–561

135 van der Greef, J., Hankemeier, T. and McBurney, R.N. (2006) Metabolomics-based systems biology and personalized medicine: moving towards n = 1 clinical trials? Pharmacogenomics **7**, 1087–1094

136 Nicholson, J.K., Wilson, I.D. and Lindon, J.C. (2011) Pharmacometabolomics as an effector for personalized medicine. Pharmacogenomics **12**, 103–111

137 Wikoff, W.R., Frye, R.F., Zhu, H., Gong, Y., Boyle, S., Churchill, E. et al. (2013) Pharmacometabolomics reveals racial differences in response to atenolol treatment. PloS One **8**, e57639

138 Woodcock, J. (2010) Assessing the clinical utility of diagnostics used in drug therapy. Clin. Pharmacol. Ther. **88**, 765–773

139 Schork, N.J. (2015) Personalized medicine: Time for one-person trials. Nature **520**, 609–611

140 Zucker, D.R., Ruthazer, R., Schmid, C.H., Feuer, J.M., Fischer, P.A., Kieval, R.I. et al. (2006) Lessons learned combining N-of-1 trials to assess fibromyalgia therapies. J. Rheumatol. **33**, 2069–2077

141 Lillie, E.O., Patay, B., Diamant, J., Issell, B., Topol, E.J. and Schork, N.J. (2011) The n-of-1 clinical trial: the ultimate strategy for individualizing medicine? Per. Med. **8**, 161–173

142 Zardavas, D. and Piccart-Gebhart, M. (2015) Clinical trials of precision medicine through molecular profiling: focus on breast cancer. Am. Soc. Clin. Oncol. Educ. Book e183–e190

143 Muller, H., Reihs, R., Zatloukal, K. and Holzinger, A. (2014) Analysis of biomedical data with multilevel glyphs. BMC Bioinf. **15**, S5